{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:15:14Z","timestamp":1794435314901,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY013574"],"award-info":[{"award-number":["EY013574"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EB000415"],"award-info":[{"award-number":["EB000415"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK101373"],"award-info":[{"award-number":["DK101373"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12974-018-1333-z","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T09:30:27Z","timestamp":1540200627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica"],"prefix":"10.1186","volume":"15","author":[{"given":"Tianjiao","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Verkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"key":"1333_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","volume":"11","author":"MC Papadopoulos","year":"2012","unstructured":"Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11:535\u201344.","journal-title":"Lancet Neurol"},{"key":"1333_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/ncpneuro0764","volume":"4","author":"S Jarius","year":"2008","unstructured":"Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008;4:202\u201314.","journal-title":"Nat Clin Pract Neurol"},{"key":"1333_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/ijms17030273","volume":"17","author":"M Jasiak-Zatonska","year":"2016","unstructured":"Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, Kozubski W. The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives. Int J Mol Sci. 2016;17:273.","journal-title":"Int J Mol Sci"},{"key":"1333_CR4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology. 1999;53:1107\u201314.","journal-title":"Neurology"},{"key":"1333_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.autrev.2018.01.001","volume":"17","author":"A Bruscolini","year":"2018","unstructured":"Bruscolini A, Sacchetti M, La Cava M, Gharbiya M, Ralli M, Lambiase A, De Virgilio A, Greco A. Diagnosis and management of neuromyelitis optica spectrum disorders - an update. Autoimmun Rev. 2018;17:195\u2013200.","journal-title":"Autoimmun Rev"},{"key":"1333_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133:349\u201361.","journal-title":"Brain"},{"key":"1333_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00401-013-1204-8","volume":"127","author":"N Asavapanumas","year":"2014","unstructured":"Asavapanumas N, Ratelade J, Verkman AS. Unique neuromyelitis optica pathology produced in naive rats by intracerebral administration of NMO-IgG. Acta Neuropathol. 2014;127:539\u201351.","journal-title":"Acta Neuropathol"},{"key":"1333_CR8","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1093\/brain\/awq177","volume":"133","author":"R Marignier","year":"2010","unstructured":"Marignier R, Nicolle A, Watrin C, Touret M, Cavagna S, Varrin-Doyer M, Cavillon G, Rogemond V, Confavreux C, Honnorat J, Giraudon P. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain. 2010;133:2578\u201391.","journal-title":"Brain"},{"key":"1333_CR9","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1084\/jem.20081241","volume":"205","author":"SR Hinson","year":"2008","unstructured":"Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, Howe CL, Pittock SJ, Lennon VA. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008;205:2473\u201381.","journal-title":"J Exp Med"},{"key":"1333_CR10","doi-asserted-by":"publisher","first-page":"14781","DOI":"10.1073\/pnas.1617859114","volume":"113","author":"SA Sagan","year":"2016","unstructured":"Sagan SA, Winger RC, Cruz-Herranz A, Nelson PA, Hagberg S, Miller CN, Spencer CM, Ho PP, Bennett JL, Levy M, et al. Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. Proc Natl Acad Sci U S A. 2016;113:14781\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1333_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00401-015-1501-5","volume":"130","author":"B Zeka","year":"2015","unstructured":"Zeka B, Hastermann M, Hochmeister S, Kogl N, Kaufmann N, Schanda K, Mader S, Misu T, Rommer P, Fujihara K, et al. Highly encephalitogenic aquaporin 4-specific T cells and NMO-IgG jointly orchestrate lesion location and tissue damage in the CNS. Acta Neuropathol. 2015;130:783\u201398.","journal-title":"Acta Neuropathol"},{"key":"1333_CR12","doi-asserted-by":"publisher","first-page":"45156","DOI":"10.1074\/jbc.M111.297275","volume":"286","author":"J Ratelade","year":"2011","unstructured":"Ratelade J, Bennett JL, Verkman AS. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem. 2011;286:45156\u201364.","journal-title":"J Biol Chem"},{"key":"1333_CR13","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/glia.22417","volume":"60","author":"A Rossi","year":"2012","unstructured":"Rossi A, Ratelade J, Papadopoulos MC, Bennett JL, Verkman AS. Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1\/M23 isoform content, or supramolecular assembly. Glia. 2012;60:2027\u201339.","journal-title":"Glia"},{"key":"1333_CR14","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain. 2002;125:1450\u201361.","journal-title":"Brain"},{"key":"1333_CR15","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/brain\/awm047","volume":"130","author":"T Misu","year":"2007","unstructured":"Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, Takahashi T, Nakashima I, Takahashi H, Itoyama Y. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007;130:1224\u201334.","journal-title":"Brain"},{"key":"1333_CR16","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/brain\/awl371","volume":"130","author":"SF Roemer","year":"2007","unstructured":"Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM, Lucchinetti CF. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130:1194\u2013205.","journal-title":"Brain"},{"key":"1333_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O\u2019Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554\u201362.","journal-title":"Lancet Neurol"},{"key":"1333_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","volume":"10","author":"MC Papadopoulos","year":"2014","unstructured":"Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10:493\u2013506.","journal-title":"Nat Rev Neurol"},{"key":"1333_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bbrc.2009.06.085","volume":"386","author":"M Kinoshita","year":"2009","unstructured":"Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T, Kumanogoh A, Kajiyama K, Yoshikawa H, Sakoda S. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun. 2009;386:623\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1333_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00401-017-1734-6","volume":"134","author":"L Tradtrantip","year":"2017","unstructured":"Tradtrantip L, Yao X, Su T, Smith AJ, Verkman AS. Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica. Acta Neuropathol. 2017;134:35\u201344.","journal-title":"Acta Neuropathol"},{"key":"1333_CR21","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.1523\/JNEUROSCI.20-19-07307.2000","volume":"20","author":"KD Whitney","year":"2000","unstructured":"Whitney KD, McNamara JO. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J Neurosci. 2000;20:7307\u201316.","journal-title":"J Neurosci"},{"key":"1333_CR22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3171\/jns.1997.87.2.0294","volume":"87","author":"CC Park","year":"1997","unstructured":"Park CC, Shin ML, Simard JM. The complement membrane attack complex and the bystander effect in cerebral vasospasm. J Neurosurg. 1997;87:294\u2013300.","journal-title":"J Neurosurg"},{"key":"1333_CR23","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.neurobiolaging.2011.12.005","volume":"33","author":"M Lee","year":"2012","unstructured":"Lee M, Guo JP, Schwab C, McGeer EG, McGeer PL. Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex. Neurobiol Aging. 2012;33:2237\u201346.","journal-title":"Neurobiol Aging"},{"key":"1333_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol. 2009;9:729\u201340.","journal-title":"Nat Rev Immunol"},{"key":"1333_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0165-5728(93)90189-6","volume":"48","author":"SJ Piddlesden","year":"1993","unstructured":"Piddlesden SJ, Morgan BP. Killing of rat glial cells by complement: deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis. J Neuroimmunol. 1993;48:169\u201375.","journal-title":"J Neuroimmunol"},{"key":"1333_CR26","first-page":"1247","volume":"79","author":"SK Singhrao","year":"1999","unstructured":"Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P. Differential expression of individual complement regulators in the brain and choroid plexus. Lab Investig. 1999;79:1247\u201359.","journal-title":"Lab Investig"},{"key":"1333_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0002-9440(10)64604-4","volume":"157","author":"SK Singhrao","year":"2000","unstructured":"Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol. 2000;157:905\u201318.","journal-title":"Am J Pathol"},{"key":"1333_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/tpj.2009.52","volume":"10","author":"MV Kolev","year":"2010","unstructured":"Kolev MV, Tediose T, Sivasankar B, Harris CL, Thome J, Morgan BP, Donev RM. Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. Pharmacogenomics J. 2010;10:12\u20139.","journal-title":"Pharmacogenomics J"},{"key":"1333_CR29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, Glogowska M, Case D, Antel JP, Owens GP, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66:617\u201329.","journal-title":"Ann Neurol"},{"key":"1333_CR30","doi-asserted-by":"publisher","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","volume":"286","author":"JM Crane","year":"2011","unstructured":"Crane JM, Lam C, Rossi A, Gupta T, Bennett JL, Verkman AS. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays. J Biol Chem. 2011;286:16516\u201324.","journal-title":"J Biol Chem"},{"key":"1333_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.neuropharm.2018.02.002","volume":"133","author":"L Tradtrantip","year":"2018","unstructured":"Tradtrantip L, Felix CM, Spirig R, Morelli AB, Verkman AS. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Neuropharmacology. 2018;133:345\u201353.","journal-title":"Neuropharmacology"},{"key":"1333_CR32","doi-asserted-by":"publisher","first-page":"e27679","DOI":"10.7554\/eLife.27679","volume":"6","author":"AJ Smith","year":"2017","unstructured":"Smith AJ, Yao X, Dix JA, Jin BJ, Verkman AS. Test of the \u2018glymphatic\u2019 hypothesis demonstrates diffusive and aquaporin-4-independent solute transport in rodent brain parenchyma. elife. 2017;6:e27679.","journal-title":"elife"},{"key":"1333_CR33","doi-asserted-by":"crossref","unstructured":"Pacifici M, Peruzzi F. Isolation and culture of rat embryonic neural cells: a quick protocol. J Vis Exp. 2012;63:e3965.","DOI":"10.3791\/3965"},{"key":"1333_CR34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/jnr.490420510","volume":"42","author":"GJ Brewer","year":"1995","unstructured":"Brewer GJ. Serum-free B27\/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. J Neurosci Res. 1995;42:674\u201383.","journal-title":"J Neurosci Res"},{"key":"1333_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40478-017-0417-9","volume":"5","author":"X Yao","year":"2017","unstructured":"Yao X, Verkman AS. Marked central nervous system pathology in CD59 knockout rats following passive transfer of Neuromyelitis optica immunoglobulin G. Acta Neuropathol Commun. 2017;5:15.","journal-title":"Acta Neuropathol Commun"},{"key":"1333_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mcn.2007.08.007","volume":"37","author":"H Zhang","year":"2008","unstructured":"Zhang H, Verkman AS. Aquaporin-4 independent Kir4.1 K+ channel function in brain glial cells. Mol Cell Neurosci. 2008;37:1\u201310.","journal-title":"Mol Cell Neurosci"},{"key":"1333_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/A:1006947322342","volume":"27","author":"DR Brown","year":"1998","unstructured":"Brown DR, Kretzschmar HA. The glio-toxic mechanism of alpha-aminoadipic acid on cultured astrocytes. J Neurocytol. 1998;27:109\u201318.","journal-title":"J Neurocytol"},{"key":"1333_CR38","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1523\/JNEUROSCI.04-10-02650.1984","volume":"4","author":"S Huck","year":"1984","unstructured":"Huck S, Grass F, Hortnagl H. The glutamate analogue alpha-aminoadipic acid is taken up by astrocytes before exerting its gliotoxic effect in vitro. J Neurosci. 1984;4:2650\u20137.","journal-title":"J Neurosci"},{"key":"1333_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0304-3940(87)90420-4","volume":"76","author":"AC Foster","year":"1987","unstructured":"Foster AC, Gill R, Kemp JA, Woodruff GN. Systemic administration of MK-801 prevents N-methyl-D-aspartate-induced neuronal degeneration in rat brain. Neurosci Lett. 1987;76:307\u201311.","journal-title":"Neurosci Lett"},{"key":"1333_CR40","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0306-4522(90)90002-L","volume":"36","author":"JW McDonald","year":"1990","unstructured":"McDonald JW, Silverstein FS, Cardona D, Hudson C, Chen R, Johnston MV. Systemic administration of MK-801 protects against N-methyl-D-aspartate- and quisqualate-mediated neurotoxicity in perinatal rats. Neuroscience. 1990;36:589\u201399.","journal-title":"Neuroscience"},{"key":"1333_CR41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40478-016-0309-4","volume":"4","author":"X Yao","year":"2016","unstructured":"Yao X, Su T, Verkman AS. Clobetasol promotes remyelination in a mouse model of neuromyelitis optica. Acta Neuropathol Commun. 2016;4:42.","journal-title":"Acta Neuropathol Commun."},{"key":"1333_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neuron.2005.09.004","volume":"48","author":"M Dubois-Dalcq","year":"2005","unstructured":"Dubois-Dalcq M, Ffrench-Constant C, Franklin RJ. Enhancing central nervous system remyelination in multiple sclerosis. Neuron. 2005;48:9\u201312.","journal-title":"Neuron"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-018-1333-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-018-1333-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-018-1333-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T03:07:51Z","timestamp":1589512071000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-018-1333-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1333"],"URL":"https:\/\/doi.org\/10.1186\/s12974-018-1333-z","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"25 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Procedures were approved by the UCSF Institutional Animal Care Use Committee (IACUC). Consent to participate is not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"294"}}